This is the protocol for a review and there is no abstract. The objectives are as follows:
The main objective of this systematic review is to evaluate the role of hypomethylating agents (i.e. 5-Aza, DAC) for untreated and previously treated patients with AML. For this purpose we will critically, systematically, and statistically analyse the efficacy of hypomethylating agents compared to best supportive care/no treatment as well as to other agents/chemotherapy regimens with regard to overall survival (OS), treatment-related mortality (TRM), complete response rate (CR), progression-free survival, quality of life, and adverse events.